Kenvue Inc. (NYSE:KVUE) Shares Sold by Rise Advisors LLC

Rise Advisors LLC cut its stake in Kenvue Inc. (NYSE:KVUE) by 28.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,253 shares of the company’s stock after selling 505 shares during the period. Rise Advisors LLC’s holdings in Kenvue were worth $29,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the company. Manchester Capital Management LLC increased its holdings in shares of Kenvue by 80.8% during the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after purchasing an additional 530 shares during the period. Mather Group LLC. bought a new stake in shares of Kenvue during the 1st quarter worth about $28,000. Riverview Trust Co acquired a new stake in shares of Kenvue in the 1st quarter worth approximately $33,000. MV Capital Management Inc. boosted its holdings in shares of Kenvue by 71.2% in the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock valued at $33,000 after acquiring an additional 642 shares in the last quarter. Finally, Salomon & Ludwin LLC bought a new stake in Kenvue during the first quarter worth approximately $33,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE opened at $21.46 on Monday. The company’s 50 day moving average price is $22.13 and its 200 day moving average price is $20.18. The company has a market capitalization of $41.09 billion, a PE ratio of 27.51, a PEG ratio of 2.76 and a beta of 1.40. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $23.55. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.04. The business had revenue of $4 billion during the quarter, compared to analyst estimates of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. Kenvue’s quarterly revenue was down .3% compared to the same quarter last year. During the same period last year, the company earned $0.32 earnings per share. Research analysts expect that Kenvue Inc. will post 1.08 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 28th. Stockholders of record on Wednesday, August 14th were issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.82%. This is a positive change from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend was Wednesday, August 14th. Kenvue’s payout ratio is currently 105.13%.

Wall Street Analyst Weigh In

KVUE has been the subject of a number of research reports. Jefferies Financial Group assumed coverage on Kenvue in a research note on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target for the company. JPMorgan Chase & Co. lifted their target price on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday. UBS Group upped their price target on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft upped their price target on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, Piper Sandler raised their price objective on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $22.20.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.